PREDICTOM is inviting general practitioners to take part in our survey. With the aim of identifying current clinical guidelines and practice for screening, identifying and diagnosing Alzheimer's Disease and early dementia, we want to hear your views.
Photo: Svein Lunde, Helse Stavanger
Published 10 February 2025
Share this article
We are inviting general practitioners to complete this short survey. It should take around 10 minutes to complete. We want to hear about your current clinical practice when managing patients who you suspect have dementia. We also ask some questions about Alzheimer’s disease and mild cognitive impairment.
Your responses will help us develop recommendations for optimising clinical practice guidelines, considering new technologies to support diagnosis and facilitators and barriers to implementation in primary care settings.
PREDICTOM clinical study has now been launched. The study is recruiting healthy people who are based in UK, Norway, Spain, Geneva, Germany, France and Brussels. Are you interested in our study? Are you uncertain about the tests involved? Why do we have these tests? Are they able to detect early-signs of dementia?
To take you insde our study, explore the different tests and methods involved, we will publish a series of news articles dedicated to the PREDICTOM clinical study. In the first article of the series, we are presenting the hearing test.
A new publication from PREDICTOM introduces a promising method to dramatically accelerate multi-contrast brain MRI scans, without sacrificing image quality. The technique could pave the way for earlier and more accessible diagnosis of neurodegenerative diseases like Alzheimer’s disease.
In a breakthrough that could reshape early detection of Alzheimer’s disease, researchers have identified a novel blood-based biomarker that may help distinguish Alzheimer’s patients from healthy individuals—potentially paving the way for simpler, less invasive diagnostics.
